The strong translational focus of our intestinal bioengineering laboratory in the area of metabolic syndrome and gastrointestinal diseases coupled with the lab’s access to the rich intellectual resources and state-of-the-art research infrastructure at Harvard-MGH has created tremendous opportunities for fruitful partnerships with biopharmaceutical companies. The types of interactions we have been involved in includes Sponsored Research Agreements (SRAs), fee-for-service research contracts, and consultations. 

Some examples of successful projects include: 

• A pre-clinical study to determine the efficacy of novel, RNAi-based obesity therapy.  

• A pre-clinical study to test the efficacy of novel stem cell treatment for end-stage organ failure. 

• A large-scale, longitudinal multi-omics profiling of serum from an animal study.  

• A periclinal study to test a novel therapy for type I and II diabetes. 

Some of the key resources that have been particularly important to those projects include: 

• Development and implementation of novel surgical models (including different types of bariatric surgery). 

• A broad range of in vivo metabolic phenotyping techniques.  

• In vivo molecular imaging (e.g., PET, CT, x-ray). 

• A broad range of transgenic and dietary-induced disease animal models. 

Please contact us to learn more and discuss your projects.